Tissue Regenix: On pathway to sustainability

Hardman & Co
[shareaholic app="share_buttons" id_name="post_below_content"]

Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of commercial regenerative medicine products for the biosurgery, orthopaedics and dental markets. 2021 results contained the early benefits of TRX’s strategic activities over the past two years – the focus on commercial relationships, capacity expansion, restructuring to service demand and recovery in elective surgeries. On the basis of continued sales progression, TRX is forecast to become EBITDA-positive in fiscal 2022 and cash-generative in 2023.

  • Strategy: Tissue Regenix is building an international regenerative medicine business around its proprietary technology platforms, underpinned by compelling clinical outcomes. Phase 1 of its manufacturing capacity expansion programme came on-stream in 2021 to satisfy demand from distribution partners for its innovative products.
  • 2021 results: Sales in fiscal 2021 were marginally ahead of our forecasts, at $19.75m, up 20% from $16.47m in 2020. The leverage effect of a strong BioRinse sales performance (+33%) saw a marked reduction in EBIT losses in 2H’21. Gross cash at the period-end was $7.7m.
  • Outlook: The 2021 performance was achieved despite the continuing impact of COVID-19 and some unforeseeable headwinds; this augurs well for the future. Progress is forecast to continue in 2022, resulting in 22% sales growth, which will drive margin expansion towards profitability by the end of 2022.
  • Risks: Early signs of recovery in the number of elective surgeries in the US were dented by the delta variant, and the emergence of another variant remains a possibility. Forecasts suggest that TRX is nearing profitability and cashflow breakeven, which would eliminate any lingering concerns about the need for a capital increase.
  • Investment summary: Tissue Regenix has a broad portfolio of innovative regenerative products that are in demand from surgeons. Completion of Phase 1 of its capacity expansion programme has comforted distribution partners and provided positive momentum. We believe TRX is well-positioned to deliver strong sales growth, which will drive margin expansion and highlight the low rating of the shares. An EV/sales multiple of 4x 2023E sales generates a valuation of $120m/£92m.

DOWNLOAD THE FULL REPORT

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    Join Hardman & Co Analyst Mark Thomas on DirectorsTalk as he examines Duke Capital's growth strategies, equity raise, and risk management insights.
    Explore ICG Enterprise Trust plc's impressive Q1 results, showcasing 14% EBITDA growth and strategic capital allocation insights from Hardman & Co Analyst.
    Explore insights on Real Estate Credit Investments Ltd (LON:RECI) as Hardman & Co's Mike Foster discusses the company's strategies and market trends.
    Explore ICG Enterprise Trust Plc's strategic growth and investment insights as Analyst Mark Thomas reviews their strong 1H FY25 performance.
    Hardman & Co analyst Mark Thomas delves into Real Estate Credit Investments' strategic shifts, market outlook, and risk factors in a detailed interview.
    Discover how NB Private Equity Partners (LON:NBPE) excels in the co-investment sector, delivering notable returns and growth in a subdued PE market.

      Search

      Search